CO6140021A2 - Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine - Google Patents

Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine

Info

Publication number
CO6140021A2
CO6140021A2 CO09050487A CO09050487A CO6140021A2 CO 6140021 A2 CO6140021 A2 CO 6140021A2 CO 09050487 A CO09050487 A CO 09050487A CO 09050487 A CO09050487 A CO 09050487A CO 6140021 A2 CO6140021 A2 CO 6140021A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
drug
nsaid
muscle relaxant
pharmaceutically acceptable
Prior art date
Application number
CO09050487A
Other languages
English (en)
Inventor
Lopez Enrique Raul Garcia-Salgado
Paniagua Angelica Arzola
Lopez Luis Fernando Poot
Rodriguez Francisco Escorcia
Hernandez Gustavo Barranco
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of CO6140021A2 publication Critical patent/CO6140021A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Abstract

1.- Una composición farmacéutica caracterizada porque las microesferas recubiertas comprenden: a) núcleos inertes recubiertos con una primera película formada por un fármaco músculo relajante, al menos un polímero adhesivo y al menos un agente plastificante; b) una segunda película polimérica retardante, al menos un agente plastificante y solución reguladora; y c) una tercera película formada por un fármaco AINE, el fármaco músculo relajante de la primera película, al menos un polímero adhesivo, al menos un agente plastificante y al menos un agente tensoactivo; en donde el fármaco músculo relajante presenta liberación modificada y el fármaco AINE presenta liberación inmediata. 2.- La composición farmacéutica de la reivindicación 1, en donde el fármaco músculo relajante presenta tiempos de concentración plasmática y de vida media diferente al tiempo de concentración plasmática y de vida media del fármaco AINE. 3.- La composición farmacéutica de la reivindicación 1, en donde el fármaco músculo relajante es tizanidina o sus sales farmacéuticamente aceptables. 4.- La composición farmacéutica de la reivindicación 1, en donde el fármaco AINE es meloxicam o sus sales farmacéuticamente aceptables. 5.- La composición farmacéutica de la reivindicación 3, en donde la concentración de tizanidina o sus sales farmacéuticamente aceptables es de 0.5 a 36% por cada unidad de dosis. 6.- La composición farmacéutica de la reivindicación 4, en donde la concentración de meloxicam o sus sales farmacéuticamente aceptables es de 2.0 a 15% por cada unidad de dosis.
CO09050487A 2006-10-18 2009-05-18 Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine CO6140021A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA06012024 2006-10-18

Publications (1)

Publication Number Publication Date
CO6140021A2 true CO6140021A2 (es) 2010-03-19

Family

ID=39313650

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09050487A CO6140021A2 (es) 2006-10-18 2009-05-18 Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine

Country Status (16)

Country Link
US (1) US20100166856A1 (es)
EP (1) EP2085076B1 (es)
AR (1) AR073435A1 (es)
AT (1) ATE499089T1 (es)
BR (1) BRPI0718368A2 (es)
CA (1) CA2670690C (es)
CL (1) CL2007002975A1 (es)
CO (1) CO6140021A2 (es)
CR (1) CR10801A (es)
DE (1) DE602007012751D1 (es)
EC (1) ECSP099348A (es)
ES (1) ES2361883T3 (es)
GT (1) GT200900089A (es)
PE (1) PE20081464A1 (es)
UY (1) UY30636A1 (es)
WO (1) WO2008047208A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009332963B2 (en) 2008-12-31 2015-02-05 Upsher-Smith Laboratories, Llc Opioid-containing oral pharmaceutical compositions and methods
WO2011034554A1 (en) * 2009-09-17 2011-03-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
PL2338473T3 (pl) 2009-12-18 2017-07-31 Mdm S.P.A. Postacie farmaceutycznej dawki tizanidyny i drogi jej podawania
BRPI1103205A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab Ltda Composição farmacêutica oral e uso da composição farmacêutica oral
EP2841072A4 (en) * 2012-04-27 2016-01-06 Troy Lab Pty Ltd POLYTHERAPY FOR ANIMALS BASED ON MELOXICAM AND XYLAZINE
US20170189374A1 (en) * 2014-07-21 2017-07-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Zaltoprofen and muscle relaxant combinations
WO2016193880A1 (en) * 2015-05-29 2016-12-08 Jubilant Generics Limited Immediate release pharmaceutical composition of tizanidine
US20190060287A1 (en) * 2017-08-28 2019-02-28 Adare Pharmaceuticals, Inc. Tizanidine formulations
CN113398096A (zh) * 2021-06-27 2021-09-17 烟台大学 一种含有美洛昔康的长效注射微球及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735369B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US20040204413A1 (en) * 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
ATE380022T1 (de) * 2001-01-31 2007-12-15 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
US8502335B2 (en) 2009-07-29 2013-08-06 Taiwan Semiconductor Manufacturing Company, Ltd. CMOS image sensor big via bonding pad application for AlCu Process

Also Published As

Publication number Publication date
CR10801A (es) 2009-07-03
AR073435A1 (es) 2010-11-10
CL2007002975A1 (es) 2008-01-04
EP2085076A1 (en) 2009-08-05
ATE499089T1 (de) 2011-03-15
EP2085076A4 (en) 2010-03-17
ES2361883T3 (es) 2011-06-24
GT200900089A (es) 2012-01-13
CA2670690C (en) 2014-12-30
US20100166856A1 (en) 2010-07-01
PE20081464A1 (es) 2008-12-31
EP2085076B1 (en) 2011-02-23
UY30636A1 (es) 2008-05-02
WO2008047208A1 (es) 2008-04-24
BRPI0718368A2 (pt) 2013-11-12
CA2670690A1 (en) 2008-04-24
ECSP099348A (es) 2009-06-30
DE602007012751D1 (de) 2011-04-07

Similar Documents

Publication Publication Date Title
CO6140021A2 (es) Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine
Rascol et al. New treatments for levodopa‐induced motor complications
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
BR112019023985A2 (pt) sistema de autocorreção e componentes e métodos relacionados
BR0309620A (pt) Métodos e formas de dosagem para liberação controlada de oxicodona
AR066420A1 (es) Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso.
GT201300166A (es) Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas
JP2016513734A5 (es)
BR112012008317A2 (pt) produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
CL2012001404A1 (es) Composicion farmaceutica que comprende microparticulas compresibles recubiertas de farmaco, un recubrimiento de liberacion modificada, enmascarador del sabor, que comprende un polimero insoluble en agua y un recubrimiento compresible con un edulcorante no polimero sobre ella; composicion de tabletas de rapida desintegracion oral; metodo de preparacion.
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
HRP20120046T1 (hr) Nerameksan za uporabu kod liječenja subakutnog tinitusa
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
Citrome Atypical antipsychotics for acute agitation: new intramuscular options offer advantages
CO5200840A1 (es) Combinacion de sustancias activas con clonidina
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
Citrome Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?
McCleane et al. Opioids for persistent noncancer pain
UY26861A1 (es) Composición de eletriptan en forma de partículas
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
AR075058A1 (es) Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion
AR070375A1 (es) Sistemas de administracion de drogas que contienen estradiol
AR096223A1 (es) Pastilla de nicotina para administración oral
Pharm et al. Formulation and Evaluation of Triamcinolone Acetonide Mucoadhesive Film as Treatment of Aphthous Stomatitis and Oral Inflammatory Diseases.